IMPLQ — IPI Legacy Liquidation Co Share News
0.000.00%
Last trade - 00:00- $0.36m
- $0.12m
- $12.65m
Brief: Impel Neuropharma Provides Updates On Trudhesatm Launch And Recent Business Highlights
Brief: Impel Neuropharma Inc - Planned Initiation Of Inp105 Proof-Of-Concept Study For Autism Spectrum Disorder In Q1 2022
Impel Neuropharma Inc reports results for the quarter ended in September - Earnings Summary
Brief: Impel Neuropharma Reports $1.24 Q3 Loss Per Share
Impel Neuropharma Inc expected to post a loss of 75 cents a share - Earnings Preview
Impel NeuroPharma rises after launch of migraine treatment
Brief: Impel Neuropharma Says Trudhesa Nasal Spray Now Available For Prescription For Acute Treatment Of Migraine
Axsome rises as U.S. FDA accepts migraine treatment application
U.S. STOCKS ON THE MOVE-Kroger, Oatly, Apple
U.S. STOCKS ON THE MOVE-McAfee, Beauty Health, Cedar Realty
U.S. STOCKS ON THE MOVE-Zscaler, Bumble, Blackstone Mortgage
U.S. STOCKS ON THE MOVE-T2 Biosystems, Endo, Affirm
Impel NeuroPharma down after pricing $45 mln equity offering
U.S. STOCKS ON THE MOVE-Virios, McAfee, Perrigo
U.S. STOCKS ON THE MOVE-Bumble, Coty, Coinbase
Brief: Impel Neuropharma Announces Launch Of Proposed Public Offering
Impel NeuroPharma jumps on U.S. approval for migraine treatment
Advisory: Alert on Impel NeuroPharma announcing August cross-border volumes withdrawn
NASDAQ RESUMED AT 09:16 AM